Atrium Therapeutics
RNAAtrium Therapeutics is a biopharmaceutical company focused on developing a new class of RNA therapeutics called Antibody Oligonucleotide Conjugates (AOCs).
Table of contents
Earnings
Next report
Aug 13, 2026 (In 2 weeks)Competitors
By market cap
By revenue growth
Profile
Atrium Therapeutics is a biopharmaceutical company focused on developing a new class of RNA therapeutics called Antibody Oligonucleotide Conjugates (AOCs). The company's proprietary platform combines the tissue-specific targeting of monoclonal antibodies with the precision of RNA-based therapies to treat rare neuromuscular and cardiac diseases. Their primary value proposition lies in overcoming traditional delivery barriers to reach tissues like skeletal and cardiac muscle that were previously difficult to treat with RNA therapeutics.
A pioneer in the AOC space with multiple programs in registrational or Phase 3 trials for indications with no currently approved disease-modifying therapies.
Questions, answered.
- What is Atrium Therapeutics 's market cap?
- Atrium Therapeutics (RNA) has a market capitalization of $197.9M and trades on NASDAQ.
- Who are Atrium Therapeutics 's competitors?
- Atrium Therapeutics 's key competitors include Dyne Therapeutics, Inc., Sarepta Therapeutics, Inc., Vertex Pharmaceuticals, Inc., and others. These companies compete in similar markets and product categories.
- Who does Atrium Therapeutics partner with?
- Atrium Therapeutics 's notable partners include Novartis AG, Bristol-Myers Squibb Company, Eli Lilly and Company, and others.
- What subsidiaries does Atrium Therapeutics have?
- Atrium Therapeutics 's subsidiaries include Bryce Therapeutics, Inc..
- Where is Atrium Therapeutics headquartered?
- Atrium Therapeutics is headquartered in United States of America and employs approximately 253 people. It has been publicly traded since 2026.